

Anti-acetylcholinesterase activity and antioxidant properties of extracts and fractions of *Carpolobia lutea*

Lucky Legbosi Nwidu, Ekramy Elmorsy, Jack Thornton, Buddhika Wijamunige, Anusha Wijesekara, Rebecca Tarbox, Averil Warren & Wayne Grant Carter

To cite this article: Lucky Legbosi Nwidu, Ekramy Elmorsy, Jack Thornton, Buddhika Wijamunige, Anusha Wijesekara, Rebecca Tarbox, Averil Warren & Wayne Grant Carter (2017) Anti-acetylcholinesterase activity and antioxidant properties of extracts and fractions of *Carpolobia lutea*, *Pharmaceutical Biology*, 55:1, 1875-1883, DOI: [10.1080/13880209.2017.1339283](https://doi.org/10.1080/13880209.2017.1339283)

To link to this article: <https://doi.org/10.1080/13880209.2017.1339283>



© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



View supplementary material [↗](#)



Published online: 19 Jun 2017.



Submit your article to this journal [↗](#)



Article views: 1845



View Crossmark data [↗](#)



Citing articles: 3 View citing articles [↗](#)

RESEARCH ARTICLE



Anti-acetylcholinesterase activity and antioxidant properties of extracts and fractions of *Carpolobia lutea*

Lucky Legbosi Nwidi^{a,b}, Ekramy Elmorsy^{b,c}, Jack Thornton^b, Buddhika Wijamunige^b, Anusha Wijesekara^b, Rebecca Tarbox^b, Averil Warren^b and Wayne Grant Carter^b

^aDepartment of Experimental Pharmacology and Toxicology, Faculty of Pharmaceutical Science, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria; ^bSchool of Medicine, University of Nottingham Medical School, Royal Derby Hospital Centre, Derby, UK; ^cDepartment of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Mansoura University, Mansoura, Egypt

ABSTRACT

Context: There is an unmet need to discover new treatments for Alzheimer's disease. This study determined the anti-acetylcholinesterase (AChE) activity, DPPH free radical scavenging and antioxidant properties of *Carpolobia lutea* G. Don (Polygalaceae).

Objective: The objective of this study is to quantify *C. lutea* anti-AChE, DPPH free radical scavenging, and antioxidant activities and cell cytotoxicity.

Materials and methods: Plant stem, leaves and roots were subjected to sequential solvent extractions, and screened for anti-AChE activity across a concentration range of 0.02–200 µg/mL. Plant DPPH radical scavenging activity, reducing power, and total phenolic and flavonoid contents were determined, and cytotoxicity evaluated using human hepatocytes.

Results: *Carpolobia lutea* exhibited concentration-dependent anti-AChE activity. The most potent inhibitory activity for the stem was the crude ethanol extract and hexane stem fraction oil (IC₅₀ = 140 µg/mL); for the leaves, the chloroform leaf fraction (IC₅₀ = 60 µg/mL); and for roots, the methanol, ethyl acetate and aqueous root fractions (IC₅₀ = 0.3–3 µg/mL). Dose-dependent free radical scavenging activity and reducing power were observed with increasing stem, leaf or root concentration. Total phenolic contents were the highest in the stem: ~632 mg gallic acid equivalents/g for a hexane stem fraction oil. Total flavonoid content was the highest in the leaves: ~297 mg quercetin equivalents/g for a chloroform leaf fraction. At 1 µg/mL, only the crude ethanol extract oil was significantly cytotoxic to hepatocytes.

Discussion and conclusions: *Carpolobia lutea* possesses anti-AChE activity and beneficial antioxidant capacity indicative of its potential development as a treatment of Alzheimer's and other diseases characterized by a cholinergic deficit.

ARTICLE HISTORY

Received 9 February 2017

Revised 6 April 2017

Accepted 3 June 2017

KEYWORDS

Anti-acetylcholinesterase; *Carpolobia lutea*; antioxidant; Alzheimer's disease

Introduction


Alzheimer's disease (AD) is the most prevalent neurodegenerative disease; with symptomology that typically includes confusion, memory loss, impaired cognitive and emotional function, and dementia. In 2015, the number of people living with dementia was estimated to be 46.8 million, with an associated economic burden of 818 billion US dollars (Alzheimer's Disease International 2015). The pathological hallmarks of AD are the deposition of extracellular amyloid plaques composed of insoluble amyloid beta (Aβ) peptides and intra-neuronal neurofibrillary tangles (NFTs) of hyperphosphorylated Tau protein. Collectively, these peptide and protein accumulations are thought to be toxic to neuronal tissue and contribute to the neuronal death and cerebral atrophy observed in AD patients (Parihar and Hemnani 2004; Ballard et al. 2011).


The aetiopathology of AD is complex and heterogeneous due to multifaceted disease mechanisms. These include mitochondrial dysfunction, redox and inflammatory stress, and alteration of neurotransmitter activities including cholinergic dysfunction

(Parihar and Hemnani 2004; Mufson et al. 2008; Ballard et al. 2011). Acetylcholine signalling is terminated within the synaptic cleft through cleavage by acetylcholinesterase (AChE). Hence, drugs that mimic acetylcholine activity (cholinomimetics), or drugs that limit acetylcholine breakdown (AChE inhibitors) have provided a therapeutic strategy to augment cholinergic signalling in AD patients (Seltzer 2006; Mufson et al. 2008; Ballard et al. 2011; Sun et al. 2012).

Physostigmine (eserine), tacrine, rivastigmine, donepezil, galantamine and huperzine A are drugs that have been employed for symptomatic treatment of AD. Their mode of action is primarily through inhibition of AChE to limit the cholinergic deficit (Sun et al. 2012). However, a search continues for other anti-AChE drugs that temper AD progression, but without induction of unwanted side effects.

Globally, natural products and secondary metabolites are utilized in traditional or alternative medicines. Herbal medicines, particularly Chinese and Indian traditional medicines, have for many centuries been specifically utilized to restore declining

CONTACT Wayne Grant Carter  wayne.carter@nottingham.ac.uk  School of Medicine, University of Nottingham Medical School, Royal Derby Hospital Centre, Derby, UK

 Supplemental data for this article can be accessed here.

© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

cognitive functions (Howes and Houghton 2003; Gurib-Fakim 2006; Adams et al. 2007; Shiksharhi et al. 2011). Medicinal plants may possess an array of secondary metabolites such as polyphenols and flavonoids with broad-spectrum pharmacological activities including cellular antioxidant activities capable of scavenging damaging free radicals. Indeed, the mechanism by which medicinal plants are able to induce therapeutic effects in AD patients may be diverse and include anti-amyloid production, anti-apoptotic, antioxidant and anti-inflammatory activities, in addition to targeting cholinergic deficits (Howes and Houghton 2003; Anekonda and Reddy 2005; Akhondzadeh and Abbasi 2006; Adams et al. 2007; Mukherjee et al. 2007; Hajiaghaee and Akhondzadeh 2012; Orhan 2013; Ansari and Khodaghali 2013; Menon et al. 2013; Shakir et al. 2013; Syad and Devi 2014). Furthermore, herbal drugs may be less toxic, display improved blood-brain barrier penetrance and exhibit beneficial synergistic effects when compared with single moiety synthetic drugs.

Systematic *in vitro* and *in vivo* screening of natural plant extracts and fractions will potentially provide new active material able to treat AD and other cognitive dysfunctions. *Carpolobia lutea* G. Don (Polygalaceae) is a perennial shrub native to West and Central Tropical Africa. It is widely distributed in rainforests and the Guinea savannah of Sierra Leone, Cameroon and Nigeria. Extracts and fractions of *C. lutea* have hitherto only been reported anecdotally to possess benefits to cognition, with the study of *C. lutea* that has included an examination of its anti-diarrheal (Nwidi, Essien et al. 2011), anti-nociceptive (Nwidi, Nwafor et al. 2011) and gastro-protective effects (Nwidi et al. 2014). Herein extracts and fractions of the stem, leaves and roots of *C. lutea* were scrutinized for therapeutic promise as an AD treatment via their ability to inhibit AChE. Additionally, extracts and fractions were examined for radical scavenging and reducing (antioxidant) activities, polyphenol and flavonoid contents determined, and *C. lutea* cytotoxicity was also assessed.

Materials and methods

Materials

All chemicals were purchased from Sigma Aldrich (Irvine, UK) unless specified otherwise.

Preparation of plant material

Plant leaves, stem and roots from *Carpolobia lutea* grown in the wild were collected in January 2015 from Itak Ikpa village in the Ikono Local Government Area of Akwa Ibom State, Nigeria. Plant parts were supplied by Mr. Okon Etefia, a traditional herbalist, attached to the Pharmacognosy Department, University of Uyo, Nigeria. Plant identification was authenticated by Dr. Margaret Bassey, Department of Botany, University of Uyo, Nigeria. A voucher specimen (UUH 999) was deposited at the University Herbarium, University of Uyo, Nigeria. Plant parts were air-dried under shade for 2 weeks at 30 °C and then powdered with a hammer mill. The pulverized material was stored at room temperature until required.

Extraction of leaf, stem-bark and root of *C. lutea*

A flow chart depicting the complete preparation of plant extracts and fractions from *C. lutea* is included in Supplementary Figure S1.

Powdered leaves (750 g) were subjected to sequential extraction by maceration for 72 h in 2.5 L of *n*-hexane to obtain the *n*-hexane fraction (*n*-HLF). The marc was air-dried and the procedure repeated with chloroform, ethyl acetate, and then ethanol solvents to obtain the corresponding chloroform leaf fraction (CHLF), ethyl acetate leaf fraction (EALF) and ethanol leaf fraction (ETLF), respectively, by filtration and concentration under reduced pressure by the use of rotary evaporation at 40 °C.

The crude ethyl acetate leaf extract (cEALF), crude ethanol leaf extract (cETLE), crude ethanol stem-bark extract (cETSE) and crude methanol root extract (cMTRE) were obtained after 72 h of maceration in each respective solvent, and filtered and concentrated under reduced pressure as above.

A hot aqueous leaf extract (HALE) and hot aqueous stem-bark extract (HASE) were obtained by the addition of 1 L of boiling water to 500 g of the powdered leaf or stem-bark material, shaking for 1 min and then the material allowed to stand for 60 min. Solvent extracts were filtered and the process repeated after 24 h. The marc obtained from the leaf extract was dried to a constant weight after 48 h at 50 °C. The residue remaining was immersed in 1 L of butanol for 72 h after which it was processed as above to yield a crude butanol leaf extract (cBULE). The yield obtained for each extract is listed in Table 1.

Fractionation of stem-bark and root of *C. lutea*

The crude ETSE of *C. lutea* (60 g) was divided into four equal aliquots, and then further fractionated by mixing with 60 g of silica gel. This material was placed in a glass column and eluted sequentially, under pressure, with 500 mL each of *n*-hexane, dichloromethane, ethyl acetate and then methanol to obtain the corresponding fractions: *n*-hexane stem fraction (*n*-HSF), dichloromethane stem fraction (DCSF), ethyl acetate stem fraction (EASF) and methanol stem fraction (MTSF), respectively.

Table 1. Percentage yield, AChE and DPPH radical scavenging IC₅₀ concentrations of stem, leaf, and root extracts and fractions of *C. lutea*.

		IC ₅₀ concentration (µg/mL)	
Extract or fraction	Yield (%)	AChE	DPPH radical scavenging
Stem			
cETSE	21.7	140	343
EASF	1.75	472	675
<i>n</i> -HSF oil	22.0	140	>1000
EASF oil	9.0	503	123
<i>n</i> -HSF	19.1	912	>1000
MTSF	52.8	142	118
MTSF oil	12.9	472	825
cSSE	22.0	811	351
DCSF	19.5	>1000	449
cETSE oil	15.6	840	334
HASE	12.5	547	504
Leaf			
cHALE	13.4	>1000	196
cETLE	7.8	478	849
CHLF	3.0	60	500
cETLF	27.1	81	>1000
cBULE	10.2	738	>1000
<i>n</i> -HLF	3.7	461	141
cEALF	3.6	500	>1000
Root			
cMTRE	44.1	3	509
CHRF	12.3	137	849
BURF	8.0	247	>1000
<i>n</i> -HRF	16.5	173	500
EARF	5.8	0.3	>1000
AQRF	20.2	2	141

The same procedure was followed to fractionate 15 g of crude ethanol stem bark extract oil (cETSE oil), *n*-hexane stem fraction oil (*n*-HSF oil), ethyl acetate stem fraction oil (EASF oil) and methanol stem fraction oil (MTSF oil). The fractions obtained were reduced in volume using rotary evaporation before drying under nitrogen flow. Thereafter, the extracts were stored in an airtight container at 4 °C until required. HASE was subjected to further sequential extraction with *n*-hexane, ethyl acetate and butanol, but only the ethyl acetate fraction of HASE yielded significant material for use.

To prepare the crude methanol root extract (cMTRE), 50 g was mixed with 100 g silica gel and placed in a glass column and sequentially eluted with *n*-hexane (*n*-hexane root fraction [*n*-HRF]), chloroform (chloroform root fraction [CHRF]), ethyl acetate (ethyl acetate root fraction, EARF), butanol (butanol root fraction, BURF) and aqueous fractions (aqueous root fraction, AQRF). The dry weight of each fraction was obtained after complete evaporation of the solvent in a fume cupboard. Extracts and fractions were stored at 4 °C until use. Each extract or fraction was reconstituted in pure (milli Q) water before use in experimental assays.

Preparation of crude saponins

From the hot aqueous stem extract (HASE), a crude saponin stem extract (cSSE) was prepared. A portion of HASE, weighing 5 g, was transferred to a conical flask and soaked with 25 mL of 20% methanol. The mixture was heated for 12 h at constant temperature of 55 °C with stirring. Thereafter, it was filtered and material extracted with 60 mL of 20% methanol. The volume of the liquid extracted was reduced to 30 mL using a water bath and transferred to a separating funnel. Diethyl ether (40 mL) was added, and, after vigorous shaking, the organic layer was removed and retained. *n*-Butanol (60 mL) was added to the aqueous fraction. The combined aqueous-butanol mixture was washed with 5% NaCl solution, before evaporation of the solvents in a fume cupboard using a water bath to yield crude saponins.

Once prepared all extracts were stored at 4 °C, with experimental assays performed within a 4-month period.

Animals

For rat brain AChE measurements, male F344 strain rats weighing between 200 and 230 g were used for experiments. Rats were maintained in cages under controlled temperature (21 ± 1 °C) and light (16 h light/8 h dark cycle) with *ad libitum* access to food intake and water. All animal procedures were approved by the University of Nottingham Local Ethical Review Committee (study reference CHE 10) and were carried out in accordance with the Animals Scientific Procedures Act (UK) 1986.

AChE activity assay

AChE activity was measured based on the method of Ellman et al. (1961), adapted for a microtitre plate format. Briefly, for each assay data point, 50 µL of 3 mM 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB), 50 µL of recombinant AChE (1 mg/mL) (Sigma, C3389, Irvine, UK) or rat brain homogenate (prepared at 10% (w/v) according to Carter et al. (2007) and Tarhoni et al. (2011)), 35 µL of 50 mM Tris/HCl pH 8.0 and 40 µL of plant extract or fraction was mixed and incubated at 37 °C. The assay was initiated by the addition of 25 µL of 15 mM

acetylthiocholineiodide (ATCI), with production of 5-thio-2-nitrobenzoate anion read at 412 nm every 5 s for 10 min using a Spectramax microplate reader (ThermoFisher, Stafford, UK). Assay reactions with plant extracts or fractions were all performed in triplicate at concentrations of 200, 20, 2, 0.2 and 0.02 µg/mL. A negative control assay performed in the absence of AChE provided a reagent blank. Eserine (Sigma, E8375, Irvine, UK) or the organophosphate pesticide, azamethiphos-oxon (QMX Laboratories Ltd, Thaxted, UK), was used as a positive control to inhibit electric eel or rat brain AChE in a dose-dependent fashion (Supplementary Figure S2). The percentage inhibition of AChE by plant extracts or fractions was calculated relative to inhibition by eserine, with the plant extract or fraction concentration producing 50% inhibition (IC₅₀) of AChE determined.

2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity

Stock solutions of extracts or fractions (5 mg/mL) were diluted to final concentrations of 200, 100, 50, 25, 12.5 and 6.25 µg/mL in ethanol. One hundred and sixty microlitre of 0.1 mM DPPH in ethanol was added to 20 µL of extract or fraction, or vitamin E (as a positive control), and the material mixed with 20 µL of water. A control solution of β-tocopherol was also assayed over a concentration range of 1.56, 0.78, 0.39, 0.195 and 0.0975 mg/mL. The mixture was incubated at 37 °C for 40 min in the dark, before reading the absorbance at 517 nm using a Spectramax microplate reader (ThermoFisher, Stafford, UK). Experimental blanks were performed in the absence of extracts or fractions. The percentage antioxidant activity was estimated as the percent DPPH radical scavenging activity. All tests were performed in triplicate and inhibition percentages reported as means ± SD.

Reducing power assessment

The reducing power of plant extracts or fractions was assessed as the ability to reduce ferric iron (Fe³⁺) to ferrous iron (Fe²⁺). Concentrations of plant extracts or fractions were prepared across a concentration range of 6.25–50 µg/mL. Aliquots of 4 µL of 5 mg/mL of each plant sample were added to 400 µL of phosphate buffer pH 7.4 and 250 µL of 1% potassium ferricyanide and incubated at 50 °C for 20 min. Then 250 µL of 10% trichloroacetic acid was added, and after mixing, samples were centrifuged at 3000 rpm for 10 min. One hundred microlitres of the supernatant was mixed with a similar volume of water and added to a microtiter plate well. Freshly prepared ferric chloride solution (20 µL) was added, and the formation of Perls' Prussian blue followed at 700 nm using a Spectramax plate reader (ThermoFisher, Stafford, UK). A blank was prepared without addition of antioxidant. All assay points were conducted in triplicates. L-Ascorbic acid was used as a positive control antioxidant. The percentage increase of reduction activity to that of control for plant extracts and fractions, and percentage of ascorbic acid reducing capacity were calculated.

Determination of total phenolic content

Total phenolic content was determined using the Folin–Ciocalteu reagent (FCR) method as described in a previous publication (Nwidi et al. 2012). Plant extract (20 µL) or fraction (20 µL) (a concentration range of 1–100 µg/mL) was mixed

with 90 μL of water, followed by the addition of 30 μL of FCR and vigorous shaking on a plate reader. Within 8 min, 60 μL of 7.5% Na_2CO_3 solution was added and the material incubated at 40 °C in a shaking incubator. After 40 min, the mixture was read in a spectrophotometer at 760 nm. Gallic acid (Sigma, CAS14991-7, Irvine, UK) was similarly processed over a concentration range of 0.1–0.5 mg/mL as a positive control, and used to generate a calibration curve for quantification of total phenolic content in extracts and fractions across the concentration range of 0.01–0.05 mg/mL. Total phenolic content was expressed as mg gallic acid equivalents/gram of plant extract or fraction (mg GAE/g).

Determination of total flavonoid content

Total flavonoid content of plant extracts was determined using quercetin as a reference compound. Briefly, 20 μL of plant extract (5 mg/mL) in ethanol was mixed in a microtiter plate well with 200 μL of 10% aluminium chloride solution and 1 M potassium acetate solution. The mixture was incubated for 30 min at room temperature before reading the absorbance at 415 nm using a Spectramax plate reader (ThermoFisher, Stafford, UK). Total flavonoid content of plant extracts or fractions was determined as mg quercetin equivalents/gram of extract or fraction (mg QUER equivalent/g).

Cell culture

Human hepatocellular carcinoma (HepG2) cells from the ATCC collection were cultured in Eagles's minimum essential media (EMEM) with 2 mM glutamine, 1% non-essential amino acids (NEAA), 10% foetal bovine serum (FBS) and antibiotics (100 $\mu\text{g}/\text{mL}$ penicillin and 100 $\mu\text{g}/\text{mL}$ streptomycin). Cells were grown in a humidified atmosphere at 37 °C and 5% CO_2 .

Cytotoxicity assays

Cells were seeded at 3×10^4 cells per well in 96-well plates. At ~80–90% confluence, extracts or fractions of *C. lutea* were added to wells at 0.1, 1, 10 and 100 $\mu\text{g}/\text{mL}$. After a 48 h treatment, media were removed and cells were incubated with fresh medium containing 0.5% thiazolyl blue tetrazolium bromide (MTT) reagent (Sigma, M2128, Irvine, UK). After 4 h at 37 °C in the humidified incubator, the media were replaced with 100 μL of isopropanol and DMSO solution [1:1 (v/v)] and the absorbance was read at 540 nm in a Spectramax plate reader (ThermoFisher, Stafford, UK). Each assay point was conducted in triplicate. Control assays performed in the absence of extract/fractions, and with extracts/fractions and in the absence of cells, were subtracted from absorbance values. The percentage of cells surviving was calculated for each concentration of *C. lutea* extract or fraction.

Statistical analysis

All statistical procedures were performed using PRISM 5 (GraphPad Software Inc., San Diego, CA). IC_{50} values were calculated using non-linear regression analysis. One-way ANOVA test with Dunn's multiple comparisons post-test were used for comparisons of different group's data. Results were expressed as means \pm SD. Statistical significance was defined as $p < 0.05$.

Results

Carpolobia lutea extracts display AChE inhibitory activity

Carpolobia lutea stem-bark, leaf and root extracts inhibited AChE activity in a dose-dependent manner (Figures 1(A–C)). At the highest dose assessed (200 $\mu\text{g}/\text{mL}$), the EASF oil and cSSE (Figure 1(A)); CHLF (Figure 1(B)); and BURF, *n*-HRF, and AQRF (Figure 1(C)) inhibited AChE to ~90–100% of that observed using 0.02 $\mu\text{g}/\text{mL}$ eserine. From these five assay concentrations (0.02–200 $\mu\text{g}/\text{mL}$), an approximate IC_{50} concentration was calculated. The roots were observed to retain the highest inhibitory potency (lowest IC_{50} concentrations) (Table 1).

The descending order of AChE inhibitory activity for the stem extracts and fractions was cETSE and *n*-HSF oil > MTSF > EASF, MTSF oil > EASF oil > HASE > cSSE > cETSE oil > *n*-HSF > DCSF. For the leaves, the descending order of AChE inhibitory potency was CHLF > cETLF > *n*-HLF > cETLE > EALF > cBULE > cHALE; and for the roots EARF > AQRF > cMTRE > CHRF > *n*-HRF > BURF.

Carpolobia lutea extracts display DPPH scavenging activity

Carpolobia lutea stem, leaf and root extracts and fractions exhibited DPPH radical scavenging activity in a concentration-dependent manner (Figures 2(A–C)). The quantitation of DPPH radical scavenging ability across the concentration range of 62.5–1000 $\mu\text{g}/\text{mL}$ was used to calculate IC_{50} concentrations (Table 1). The MTSF, *n*-HLF and AQRF displayed the most potent DPPH radical scavenging activity (lowest IC_{50} s) for the stem, leaves and roots, respectively (Table 1). Collectively, for the stem, the descending order of DPPH radical scavenging activity was the following: MTSF > EASF oil > cETSE oil > cETSE > cSSE > DCSF > HASE > EASF > MTSF oil > *n*-HSF, *n*-HSF oil (Table 1). For the leaves, DPPH radical scavenging activity was in the descending order: *n*-HLF > cHALE > CHLF > cETLE > cBULE, EALF, cETLF; and for the roots: AQRF > *n*-HRF > cMTRF > CHRF > EARF, BURF.

Carpolobia lutea extracts display reducing (antioxidant) activity

Carpolobia lutea stem, leaf and root extracts and fractions displayed reducing (antioxidant) capacity in a concentration-dependent fashion (Figures 3(A–C)). Some extracts and fractions of stem and leaves displayed no reductive capacity, or indeed were oxidative in nature (values below zero) for concentrations of 6.25–25 $\mu\text{g}/\text{mL}$. At the highest concentration examined (50 $\mu\text{g}/\text{mL}$), the reducing capacity of the stem extracts and fractions was DCSF > EASF oil > cSSE > EASF > cETSE > ETSE oil > HASE > MTSF > MTSF oil > *n*-HSF oil > *n*-HSF (Figure 3(A)). Notably the DCSF had a higher percentage reducing capacity than the assayed standard, ascorbic acid (vitamin C). At 50 $\mu\text{g}/\text{mL}$, the reducing capacity of the leaf extracts and fractions was cHALE > EALF > cETLE > CHLF > *n*-HLF > ETLF > cBULE (Figure 3(B)). For the root extracts and fractions, the order was BURF > EARF > AQRF > MTRE > *n*-HRF > CHRF. Collectively, the roots displayed the greatest reducing capacity, with both BURF and EARF possessing comparable reductive capacity to vitamin C.




Figure 1. AChE inhibitory activity of plant extracts and fractions of *C. lutea*. Plant inhibition of AChE was measured using a modified Ellman assay, with percentage inhibition of AChE calculated relative to eserine. (A) Stem, (B) leaf and (C) root. Results are expressed as means \pm SEM for three separate experiments at each concentration.




Figure 2. DPPH radical scavenging activity of plant extracts and fractions of *C. lutea*. Plant antioxidant activity was assessed via the percent inhibition (radical scavenging) of DPPH. Vitamin E was used as a positive control. (A) Stem, (B) leaf, and (C) root. Results are expressed as means \pm SEM for three separate experiments at each concentration.




Figure 3. Reductive capacity of plant extracts or fractions of *C. lutea*. Plant reducing power was assessed via the ability to reduce ferric (Fe^{3+}) to ferrous (Fe^{2+}) iron. The percentage increase of reductive capacity with increasing plant extract concentration was determined. Ascorbic acid (vitamin C) was used as a positive control. (A) Stem, (B) leaf, and (C) root. Results are expressed as means \pm SEM for three separate experiments at each concentration.

Total phenolic and total flavonoid content of *C. lutea*

The total phenolic content measured as mg gallic acid equivalents/gram and total flavonoid content measured as mg quercetin equivalents/gram were determined for each extract and fraction (Table 2). For the stem, the *n*-HSF oil and the DCSF possessed the highest total phenolic content. The total phenolic content decreased in the following order: *n*-HSF oil > DCSF > cETSE > MTSF > *n*-HSF > cETSE oil > HASE > EASF > MTSF oil > cSSE > EASF oil. Similarly, the *n*-HSF oil possessed the highest total flavonoid content; with a descending order of *n*-HSF oil > *n*-HSF > MTSF oil > EASF > cSSE > cETSE oil > cETSE > EASF oil > DCSF > HASE > MTSF.

For the leaves, the total phenolic content was cBULE > *n*-HLF > cETLE > cHALE > CHLF > cETLF > EALF; and, for total flavonoid content, CHLF > *n*-HLF > EALF > cETLF > cETLE > cBULE > cHALE.

For the roots, the total phenolic content was BURF > *n*-HRF > EARF > cMTRE > CHRF > AQRF; and, for total flavonoid content, BURF > *n*-HRF > CHRF > EARF > AQRF > cMTRE.

Assessment of *C. lutea* cytotoxicity

Carpolobia lutea stem, leaf or root extracts and fractions were evaluated for cytotoxicity to human liver HepG2 cells over a broad concentration range of 0.1–100 µg/mL. Evaluation of cytotoxicity included extracts/fractions of relatively potent AChE inhibitory activity (cETSE, *n*-HSF Oil, MTSF, cMTRE, CHRF, EARF), DPPH radical scavenging activity (MTSF, cHALE) and high phenolic content (*n*-HSF Oil, DCSF). At the highest dose employed, HepG2 cell viability was still ~100% with some of the stem (cETSE, *n*-HSF Oil, MTSF, MTSF Oil) and root

(cMTRE, EARF) extracts/fractions, with IC_{50} s of >2000 µg/mL (Table 3). However, certain stem (EASF, *n*-HSF, DCSF, cETSE Oil, HASE), leaf (cHALE) or root (CHRF) extracts/fractions displayed dose-dependent inhibition of cell viability albeit with relatively high IC_{50} values (~691 to >2000 µg/mL). Interestingly, incubation of cells with several plant extracts/fractions (cETSE, MTSF, cBULE, cMTRE, EARF) at concentrations of 0.1–10 µg/mL triggered a significant increase of cell metabolic activity with MTT assay results above 100% (Table 3).

Discussion and conclusions

The prevalence of neurodegenerative disease is increasing due to an ever ageing population, with the number of individuals living with dementia expected to double every 20 years, reaching 74.7 million by 2030 (Alzheimer's Disease International 2015). The World Health Organization has recognized this as a global healthcare problem of potentially epidemic proportion (Global Health and Aging report 2011). Treatment of neurodegenerative diseases such as AD is currently limited, and new medicines that alleviate symptomology and restrict disease progression are required.

An ethnopharmacological approach of systematic screening of natural products is a cost effective strategy of developing novel drug treatments. Indeed, rivastigmine and galantamine are FDA-approved AChE inhibitors that were derived from medicinal plants, and are utilized for the treatment of mild to moderate AD (Muñoz-Torrero 2008; Ballard et al. 2011; Syad and Devi 2014). Our screening study demonstrated that extracts and fractions of the stems, leaves and roots of *C. lutea* inhibit AChE in a dose-dependent fashion. The cETSE, MTSF and *n*-HSF oil from

the stem-bark were approximately equipotent at inhibiting AChE with IC_{50} values of $\sim 140 \mu\text{g/mL}$. Two leaf fractions, CHLF and ETLE, exhibited even lower IC_{50} values of 60 and $81 \mu\text{g/mL}$, respectively. For roots, the AQR, EARF and MTRE were the most potent inhibitors of AChE, with IC_{50} values of $0.3\text{--}3.0 \mu\text{g/mL}$. Pure eserine (physostigmine) at $0.02 \mu\text{g/mL}$ ($\sim 72 \text{ nM}$) was employed as a positive control in our assays. At this concentration, eserine was able to inhibit electric eel AChE to approaching 100% (results not included), and likewise inhibit rat brain AChE (Supplementary Data Figure S2). Human brain AChE should also be inhibited to approaching 100% at this eserine concentration (IC_{50} of $\sim 14 \text{ nM}$) (Thomsen et al. 1991; Triggle et al. 1998). Hence, root extracts of *C. lutea* show particular promise for provision of a useful AChE inhibitor since in a partially purified

state their IC_{50} was only an order of magnitude less potent than eserine. By comparison, the anti-AChE drug tacrine has an IC_{50} value of $\sim 1 \mu\text{M}$ against human AChE (Thomsen et al. 1991), approximately 72 times less potent than eserine.

In addition to notable AChE inhibitory activity, our study also highlights the existence and activity of *C. lutea* secondary metabolites. *Carpobrotus lutea* contains polyphenols and flavonoids (Table 2), compounds that exhibit scavenging (antioxidant) activities. These antioxidants may counter free radical damage produced during metabolism and for which radical levels may be exacerbated in AD (Parihar and Hemnani 2004; Zhao and Zhao 2013). For comparison to standards, the majority of stem and root extracts/fractions at a 1 mg/mL concentration displayed DPPH free radical scavenging ability comparable with vitamin E (Figures 2(A,C)). Likewise, reductive (antioxidant capacity) of certain stem (EASF oil, cSSE, DCSF) and root (BURF, EARF) extracts/fractions at $50 \mu\text{g/mL}$ was comparable with vitamin C (ascorbic acid) (Figures 3(A,C)). The majority of leaf extracts/fractions were relatively weak DPPH radical scavengers, in keeping with a previous preliminary screening of *C. lutea* leaves (Nwidi et al. 2012). At concentrations of $6.25\text{--}25 \mu\text{g/mL}$, some of the stem and leaf extracts of *C. lutea* were oxidative in nature (Figure 3(A,B)), indicative of the presence of pro- as well as anti-oxidant chemicals.

There is a growing list of plants that have similarly been screened for anti-AChE activity and that also possess beneficial natural antioxidants (secondary metabolites) that can complement endogenous antioxidant systems (Mukherjee et al. 2007; Calderón et al. 2010; Şenol et al. 2010; Hlila et al. 2013; Natarajan et al. 2013; Syad and Devi 2014). By comparison with these, *C. lutea* roots exhibit sub-micromolar IC_{50} values and are, therefore, among the more potent phytochemical inhibitors of AChE (Natarajan et al. 2013; Pinho et al. 2013; Tundis et al. 2016).

Some plant constituents are also able to inhibit butyrylcholinesterase (BChE) *in vitro* (Pinho et al. 2013; Tundis et al. 2016). The AD drug rivastigmine is a weak inhibitor of both AChE and BChE *in vitro* (Pinho et al. 2013), but *in vivo*, the AD drugs huperzine A and donepezil specifically inhibit AChE rather than BChE (Duysen et al. 2007), and similarly, *in vitro*, AChE displays a 1000-fold higher affinity than BChE to inhibition by huperzine A (Ashani et al. 1992). It has been suggested that BChE activity

Table 2. Total phenolic and total flavonoid content of stem, leaf and root extracts and fractions of *C. lutea*.

Extract or fraction	Total phenolic content (mg GAE/g)	Total flavonoid content (mg QUER E/g)
Stem		
cETSE	235.33 ± 0.01	30.59 ± 0.01
EASF	177.23 ± 0.01	100.37 ± 0.20
<i>n</i> -HSF oil	632.28 ± 0.00	196.21 ± 0.10
EASF oil	3.00 ± 0.00	29.54 ± 0.20
<i>n</i> -HSF	226.46 ± 0.00	176.87 ± 0.20
MTSF	234.99 ± 0.02	1.75 ± 0.01
MTSF oil	128.42 ± 0.01	116.49 ± 0.04
cSSE	26.0 ± 0.00	78.72 ± 0.30
DCSF	581.49 ± 0.00	19.59 ± 0.01
cETSE oil	198.50 ± 0.00	40.85 ± 0.01
HASE	178.37 ± 0.00	11.94 ± 0.02
Leaf		
cHALE	256.04 ± 0.01	17.04 ± 0.00
cETLE	257.02 ± 0.02	24.69 ± 0.02
CHLF	144.67 ± 0.01	296.68 ± 0.03
cETLF	120.32 ± 0.01	63.28 ± 0.02
cBULE	292.29 ± 0.01	19.21 ± 0.00
<i>n</i> -HLF	285.63 ± 0.00	246.22 ± 0.20
cEAL	100.85 ± 0.00	118.23 ± 0.00
Root		
cMTRE	246.28 ± 0.00	9.36 ± 0.01
CHRF	33.40 ± 0.00	104.52 ± 0.08
BURF	462.00 ± 0.00	193.02 ± 0.00
<i>n</i> -HRF	357.00 ± 0.00	123.06 ± 0.00
EARF	296.50 ± 0.00	53.55 ± 0.01
AQR	28.00 ± 0.00	44.39 ± 0.00

Table 3. Influence of plant extracts or fractions of *C. lutea* upon HepG2 cell viability.

Extracts or fractions	0.1 $\mu\text{g/mL}$	1 $\mu\text{g/mL}$	10 $\mu\text{g/mL}$	100 $\mu\text{g/mL}$	IC_{50} ($\mu\text{g/mL}$)
cETSE	101.20 ± 7.34	$118.23 \pm 9.23^*$	$121.34 \pm 4.35^{***}$	97.23 ± 2.34	> 2000
EASF	105.60 ± 10.24	102.40 ± 9.26	95.60 ± 7.25	$35.5 \pm 12.24^{***}$	~ 754
<i>n</i> -HSF oil	99.80 ± 11.25	103.20 ± 9.35	115.43 ± 7.36	93.23 ± 8.35	> 2000
<i>n</i> -HSF	101.30 ± 8.35	113.54 ± 13.24	$74.30 \pm 8.35^{**}$	$46.2 \pm 5.36^{***}$	~ 895
MTSF	105.60 ± 7.24	$130.30 \pm 12.13^*$	112.20 ± 12.34	97.56 ± 10.23	> 2000
MTSF oil	105.40 ± 6.35	113.50 ± 6.35	110.60 ± 9.39	95.65 ± 9.34	> 2000
DCSF	107.50 ± 6.45	103.40 ± 7.35	98.50 ± 10.24	$42.34 \pm 8.34^{***}$	~ 843
cETSE oil	$87.13 \pm 8.34^*$	$79.23 \pm 5.54^{***}$	$64.82 \pm 4.35^{***}$	$56.20 \pm 3.34^{***}$	~ 1010
HASE	101.23 ± 11.32	99.65 ± 6.34	91.26 ± 9.45	$85.45 \pm 8.36^{**}$	> 2000
cBULE	$108.15 \pm 0.57^{**}$	$110.72 \pm 3.64^*$	$112.49 \pm 3.14^{**}$	$73.39 \pm 7.49^{**}$	> 2000
cEAL	102.87 ± 5.06	94.85 ± 1.19	104.89 ± 4.36	89.13 ± 5.29	> 2000
cHALE	99.34 ± 12.23	98.12 ± 10.32	$78.34 \pm 8.34^{**}$	$61.23 \pm 10.2^{***}$	> 2000
cMTRE	101.23 ± 9.24	$123.20 \pm 8.65^*$	112.48 ± 5.34	99.50 ± 12.34	> 2000
CHRF	99.30 ± 9.35	92.35 ± 10.23	82.50 ± 12.23	$32.14 \pm 10.24^{***}$	~ 691
EARF	101.70 ± 8.24	112.64 ± 6.45	$122.40 \pm 7.35^*$	95.23 ± 13.23	> 2000

Hep G2 cells were incubated with plant extracts or fractions at the concentrations specified for 48 h and the percentage of viable cells determined using a MTT assay. Extract or fraction was assessed at least in triplicate across a $0.1\text{--}100 \mu\text{g/mL}$ concentration range, and an approximate IC_{50} calculated. For marked significance from controls,

* $p < 0.05$,

** $p < 0.01$,

*** $p < 0.001$.

may not normally be needed for acetylcholine hydrolysis since BChE-deficient mice are healthy, and similarly, humans with no BChE activity do not display signs of ill-health, or a loss of fertility or longevity (Manoharan et al. 2007; Lockridge 2015). BChE may certainly substitute for AChE upon requirement since AChE knockout mice are also viable (Mesulam et al. 2002), but the importance of anti-BChE activity in AD drug development will need further substantiation; and so the ability of *C. lutea* to inhibit BChE has not yet been investigated further.

A recent *in vivo* study by Ajiwhien and Bisong (2013) administered a low-dose (1500 mg/kg p.o.) of *C. lutea* root extract to mice and reported cognitive memory enhancing activity, and this may reflect the potent anti-AChE activity described herein. At this dose of *C. lutea* roots, no toxicity to mice was reported (Ajiwhien and Bisong 2013), and our *in vitro* study suggests that at levels producing AChE inhibition (0.1–1 µg/mL), the majority of *C. lutea* extracts/fractions are not toxic to human liver cells (Table 3).

Carpolobia lutea possesses flavonoids (Table 2): polyphenols that include flavones and isoflavones that are notable anti-AChE inhibitors (Uriarte-Pueyo and Calvo 2011; Pinho et al. 2013). However, there was not a direct correlation between total flavonoid levels in either stem, leaf or roots with corresponding anti-AChE inhibitory potency (Table 1). Thus, we cannot yet comment on the active agent that produces AChE inhibition, but similar to other studies (Mukherjee et al. 2007; Calderón et al. 2010; Şenol et al. 2010; Hlila et al. 2013; Natarajan et al. 2013; Syad and Devi 2014), initial screening provides a means to identify fractions suitable for further purification and active agent identification. Thus, *C. lutea* remains a potentially beneficial pharmacotherapy that could be further developed for the treatment of AD and/or other diseases such as Parkinson's and myasthenia gravis that also require agents able to address cholinergic deficits.

Acknowledgements

The authors are thankful to the following funding sources: International Visiting Fellowship grants to W. G. C. to support L. L. N. and E. E.; The Physiological Society summer scholarship grant to W. G. C. to support J. T.; A. W. is a Commonwealth Scholar, funded by the UK government.

Disclosure statement

The authors can confirm that there are no conflicts of interest associated with the production or publication of this manuscript.

References

- Adams M, Gmünder F, Hamburger M. 2007. Plants traditionally used in age related brain disorders—a survey of ethnobotanical literature. *J Ethnopharmacol.* 113:363–381.
- Ajiwhien IO, Bisong SA. 2013. Effect of ethanolic extract of *Carpolobia lutea* G. Don (Polygalaceae) root on learning and memory in CD1 mice. *Niger J Physiol Sci.* 28:141–145.
- Akhondzadeh S, Abbasi SH. 2006. Herbal medicine in the treatment of Alzheimer's disease. *Am J Alzheimers Dis Other Dement.* 21:113–118.
- Alzheimer's Disease International. 2015. World Alzheimer Report 2015: The Global Impact of Dementia. [accessed 2016 Oct 4]. <http://www.alz.co.uk/research/world-report-2015>.
- Anekonda TS, Reddy PH. 2005. Can herbs provide a new generation of drugs for treating Alzheimer's disease? *Brain Res Brain Res Rev.* 50:361–376.
- Ansari N, Khodaghali F. 2013. Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect. *Curr Neuropharmacol.* 11:414–429.
- Ashani Y, Peggins JO, Doctor BP. 1992. Mechanism of inhibition of cholinesterases by huperzine A. *Biochem Biophys Res Commun.* 184:719–726.
- Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. 2011. Alzheimer's disease. *Lancet.* 377:1019–1031.
- Calderón AI, Cubilla M, Espinosa A, Gupta MP. 2010. Screening of plants of Amaryllidaceae and related families from Panama as sources of acetylcholinesterase inhibitors. *Pharm Biol.* 48:988–993.
- Carter WG, Tarhoni M, Rathbone AJ, Ray DE. 2007. Differential protein adduction by seven organophosphorus pesticides in both brain and thymus. *Hum Exp Toxicol.* 26:347–353.
- Duysen EG, Li B, Darvesh S, Lockridge O. 2007. Sensitivity of butyrylcholinesterase knockout mice to (–)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. *Toxicology.* 233:60–69.
- Ellman GL, Courtney KD, Andres V, Featherstone RM. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol.* 7:88–95.
- Global Health and Aging report. 2011. World Health Organization. [accessed 2016 Oct 4]. www.who.int/ageing/publications/global_health.pdf.
- Gurib-Fakim A. 2006. Medicinal plants: traditions of yesterday and drugs of tomorrow. *Mol Aspects Med.* 27:1–93.
- Hajiaghache R, Akhondzadeh S. 2012. Herbal medicine in the treatment of Alzheimer's disease. *J Med Plants.* 11:41.
- Hlila MB, Omri A, Jannet HB, Lamari A, Aouni M, Selmi B. 2013. Phenolic composition, antioxidant and anti-acetylcholinesterase activities of the Tunisian *Scabiosa arenaria*. *Pharm Biol.* 51:525–532.
- Howes M-JR, Houghton PJ. 2003. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. *Pharmacol Biochem Behav.* 75:513–527.
- Lockridge O. 2015. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. *Pharmacol Ther.* 148:34–46.
- Manoharan I, Boopathy R, Darvesh S, Lockridge O. 2007. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. *Clin Chim Acta.* 378:128–135.
- Menon JS, Krishnakumar K, Dineshkumar B, John A, Paul D, Cherian J. 2013. Herbs for Alzheimer disease – a review. *Int J Res Plant Sci.* 3:54–56.
- Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. 2002. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. *Neuroscience.* 110:627–639.
- Mufson EJ, Counts SE, Perez SE, Ginsberg SD. 2008. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. *Expert Rev Neurother.* 8:1703–1718.
- Mukherjee PK, Kumar V, Mal M, Houghton PJ. 2007. Acetylcholinesterase inhibitors from plants. *Phytomedicine.* 14:289–300.
- Muñoz-Torrero D. 2008. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. *Curr Med Chem.* 15:2433–2455.
- Natarajan S, Shunmugiah KP, Kasi PD. 2013. Plants traditionally used in age-related brain disorders (dementia): an ethnopharmacological survey. *Pharm Biol.* 51:492–523.
- Nwidu LL, Aprioku JS, Guluye FH. 2014. Study on radical scavenging and gastroprotective effects of ethanolic stem-bark extract of *Carpolobia lutea* in rodents. *W J Pharm Res.* 3:73–88.
- Nwidu LL, Cilli EM, Vilegas W. 2012. Amino acid, antioxidant and ion profiles of *Carpolobia lutea* leaf (Polygalaceae). *Trop J Pharm Res.* 11:807–813.
- Nwidu LL, Essien GE, Nwafor PA, Vilegas W. 2011. Antidiarrheal mechanism of *Carpolobia lutea* leaf fractions in rats. *Pharm Biol.* 49:1249–1256.
- Nwidu LL, Nwafor PA, da Silva VC, Rodrigues CM, dos Santos LC, Vilegas W, Nunes-de-Souza RL. 2011. Anti-nociceptive effects of *Carpolobia lutea* G. Don (Polygalaceae) leaf fractions in animal models. *Inflammopharmacology.* 19:215–225.
- Orhan IE. 2013. Nature: a substantial source of auspicious substances with acetylcholinesterase inhibitory action. *Curr Neuropharmacol.* 11:379–387.
- Parihar MS, Hemnani T. 2004. Alzheimer's disease pathogenesis and therapeutic interventions. *J Clin Neurosci.* 11:456–467.
- Pinho BR, Ferreres F, Valentão P, Andrade PB. 2013. Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment. *J Pharm Pharmacol.* 65:1681–1700.
- Seltzer B. 2006. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. *J Int Med Res.* 34:339–347.
- Şenol FS, Yilmaz G, Şener B, Koyuncu M, Orhan I. 2010. Preliminary screening of acetylcholinesterase inhibitory and antioxidant activities of Anatolian *Heptaptera* species. *Pharm Biol.* 48:337–341.

- Shakir T, Coulibaly AY, Kehoe PG. 2013. An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease. *Am J Neurodegener Dis*. 2:70–88.
- Shikshartha AN, Mittal S, Ramana J. 2011. Systematic review of herbals as potential memory enhancers. *Int J Res Pharm Biomed Sci*. 2:918–925.
- Sun X, Jin L, Ling P. 2012. Review of drugs for Alzheimer's disease. *Drug Discov Ther*. 6:285–290.
- Syad AN, Devi KP. 2014. Botanicals: a potential source of new therapies for Alzheimer's disease. *Botanicals: Targets Therapy*. 4:11–26.
- Tarhoni MH, Vigneswara V, Smith M, Anderson S, Wigmore P, Lees J, Ray DE, Carter WG. 2011. Detection, quantification, and microlocalisation of targets of pesticides using microchannel plate autoradiographic imagers. *Molecules*. 16:8535–8551.
- Thomsen T, Kaden B, Fischer JP, Bickel U, Barz H, Gusztosy G, Cervos-Navarro J, Kewitz H. 1991. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. *Eur J Clin Chem Clin Biochem*. 29:487–492.
- Triggle DJ, Mitchell JM, Filler R. 1998. The pharmacology of physostigmine. *CNS Drug Rev*. 4:87–136.
- Tundis R, Bonesi M, Menichini F, Loizzo MR. 2016. Recent knowledge on medicinal plants as source of cholinesterase inhibitors for the treatment of dementia. *Mini Rev Med Chem*. 16:605–618.
- Uriarte-Pueyo I, Calvo MI. 2011. Flavonoids as acetylcholinesterase inhibitors. *Curr Med Chem*. 18:5289–5302.
- Zhao Y, Zhao B. 2013. Oxidative stress and the pathogenesis of Alzheimer's disease. *Oxid Med Cell Longev*. 2013:316523.